Related Experiment Video
Updated: Sep 17, 2025
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Development of a Benzoxazine-derived Inhibitor Targeting Epithelial-to-Mesenchymal Transition in Lung Cancer
Naphatson Phansom1,2, Zin Zin Ei2,3, Bhurichaya Innets2,3
1Graduate Program of Biomedical Sciences, Faculty of Science, Rangsit University, Pathumthani, Thailand.
Background/Aim:
The epithelial-to-mesenchymal transition (EMT) plays an essential role in lung cancer metastasis. This study aimed to explore the EMT inhibitory effect of the new compound 6,6'-(butylazanediyl) bis (methylene) bis (2,4-dimethylphenol) (2,4-diMBD).
Materials And Methods:
Cell survival and proliferation were determined using cell viability and colony formation assays. Migration was analyzed using a wound-healing assay. The expression of proteins and mRNAs was examined using immunofluorescence assay and real-time quantitative PCR.
Results:
2,4-diMBD significantly suppressed colony formation and cell migration. In relation to its anti-migratory activity, we found that 2,4-diMBD decreased Snail, Slug, and zinc finger E-box binding homeobox (ZEB) levels at both the mRNA and protein levels, indicating EMT suppression in human lung cancer cells.
Conclusion:
2,4-diMBD exerts anti-metastatic properties in lung cancer cells via EMT inhibition, and is a promising compound for the treatment of lung cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...